PTC THERAPEUTICS INC (PTCT) is up +5.27% in the latest session. Our newswire has captured 1 story on PTCT across 1 source in the last 36 hours, with AI sentiment reading mixed (avg 50/100).
PTCT stock is down 8.74% to $68.92 in a session marked by a sharp decline from its opening price. The stock opened with a 0.9% gap down and quickly dropped to a low of $64.57 before trading closed at $68.92. The move follows the company’s second-quarter 2026 earnings report and a corporate update that included a raised sales forecast, but also a leadership change and mixed analyst reactions.
PTC Therapeutics reported Q2 2026 results with total revenue of $361 million, including $239 million in product revenue. The company raised its full-year 2026 total revenue guidance to $1.18 billion to $1.28 billion. However, the 8-K filing disclosed the departure of a director and the appointment of certain officers, signaling internal changes. The earnings call, held on July 30, 2026, featured comments from company executives, but the market reacted negatively, with the stock falling sharply during the session. The PR Newswire announcement highlighted the robust Q2 performance, but the broader market response was bearish, as reflected in the intraday price action.
The stock opened at $74.85 and fell to $64.57, a level not seen since early August. Volume so far is 0.9 million shares, which is 0.5 times the 3-month daily average. The stock is currently trading within its 52-week range of $43.17 to $90.87. Recent insider transactions include 14 sales totaling $16.6 million in the last 90 days, with the most recent filing on July 16. Congressional trades include two recent purchases by Donald J. Trump in March and February 2026, and a sale in January.
The stock is set to continue trading with elevated volatility. Investors should monitor the company’s upcoming earnings and any further leadership developments. Analyst coverage remains mixed, with Wells Fargo and Cantor Fitzgerald maintaining overweight ratings while RBC Capital maintains a sector perform rating.
AI-assisted analysis composed exclusively from headlines and data on the Top Tier newswire. Public view is delayed 4 hours from real time. Not financial advice.
WARREN, N.J., Sept. 25, 2026 /PRNewswire/ -- PTC Therapeutics, Inc. (NASDAQ: PTCT) today announced that on Sept. 22, 2026, the company approved non-statutory stock options to purchase an aggregate of 51,270 shares of its common stock and 37,995 restricted stock units ("RSUs"), each...
PTC THERAPEUTICS INC (PTCT) is up +5.27% in the latest session. Our newswire has captured 1 story on PTCT across 1 source in the last 36 hours, with AI sentiment reading mixed (avg 50/100). The most recent driver: "PTC Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)" (StockTitan).
Top Tier Newswire does not give financial advice. Our AI sentiment across the last 36 hours of PTCT coverage reads 50/100 over 1 stories; treat it as a research signal and do your own diligence.
The data sections refresh continuously as the newswire lands coverage; the written analysis is published once per trading day. Pro subscribers additionally get real-time push alerts, watchlists, and the full live terminal.
More on PTCT: full news and sentiment history. Sentiment scores are AI-derived research signals, not financial advice.